Skip to Main Content

Paper Details

Comparative effectiveness of higher adalimumab maintenance therapy versus standard dose in anti-tumor necrosis factor experienced Crohn's disease patients: A propensity-score matched cohort analysis.
J Gastroenterol Hepatol
0
2021
CD, Crohn's disease, Patients, SD, TNF, adalimumab, anti-TNF, anti-tumor necrosis factor, participants, patient, patients, tumor necrosis factor
Author NameAffiliation
Neeraj NarulaFarncombe Family Digestive Health Research Institute, McMaster University
Mark S SilverbergMount Sinai Hospital IBD Centre
Mark S SilverbergUniversity of Toronto
  • 1 - 3

Datasets

Release 1.2